• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Cosette Pharmaceuticals, Inc.

    Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Tickers PTN
    Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone® 5%
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo
    From Cosette Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.